Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-PAD trial of mirabegron for peripheral arterial disease
ACTRN12619000423112Phase 2Recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteriosclerosis obliterans comparing Mirabegron with Placebo (2 arms). Primary endpoint: Change in peak walking time. Started Mar 2019; status: recruiting.
02
Drugs
mirabegron
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on ACTRN12619000423112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000423112.